Adicet bio to present at upcoming investor conferences

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (car) t cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in august. details of the events are as follows: btig biotech conference, august 8-9, 2022 chen schor, president & ceo, will participate in a fireside ch
ACET Ratings Summary
ACET Quant Ranking